Changes in Hong Kong stocks | Laikai Pharmaceutical-B (02105) rose more than 4% and made significant progress in the self-developed LAE102 obesity phase I clinical trial

The Zhitong Finance App learned that Laikai Pharmaceutical-B (02105) rose by more than 4%. As of press release, it had risen 4.39% to HK$5.94, with a turnover of HK$10.910,000.

According to the news, Lai Kai Pharmaceutical announced today that its self-developed LAE102 (ActRIa monoclonal antibody) has made significant progress in phase I clinical trials for overweight/obesity in China: the subcutaneous injection (SC) portion of the single dose escalation (SAD) study has begun. This phase I clinical trial is a randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of LAE102 injection in healthy adult subjects and overweight/obese subjects through both intravenous (IV) and subcutaneous (SC) administration methods.

According to the company, as of September 30, 2024, more than half of the intravenous infusion cohorts had completed administration, and early signs of target binding and changes in expected PD biomarkers were observed in the low dose group. The subcutaneous injection research section has been initiated this time, and it is expected that a single dose escalation study will be completed by the end of 2024. Currently, LAE102 has been approved by China and the US for new drug clinical trials (IND) for obesity indications, and phase I clinical research is progressing at full speed.